{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:36Z","timestamp":1788044316355,"version":"build-2784847793"},"reference-count":12,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Interleukin 27 (IL-27) is an initiator of the Th1 response and inhibits inflammatory responses. In a mouse model of asthma, administration of IL-27 reduced eosinophil numbers in bronchoalveolar lavage fluid and airway hyperresponsiveness. However, it is unclear whether administration of IL-27 can inhibit symptoms of allergic diseases and allergic rhinitis as a therapeutic agent. Therefore, we investigated the in vivo effect of IL-27 on nasal symptoms and allergic rhinitis. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Mice sensitized and challenged with ovalbumin (OVA) antigen received intranasal administration of IL-27. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Intranasal administration of IL-27 significantly suppressed the number of sneezes and nasal rubbing movements, the number of eosinophils, OVA-specific T-cell responses in cervical lymph nodes, production of IL-4 and IL-5, and OVA-specific IgE in sera, compared with the administration of PBS alone. The production of IL-10 and IL-35, the percentage of CD25+Foxp3+ cells, and the gene expression of Foxp3 in mice that received intranasal administration of IL-27 were also significantly higher than those in mice that received only PBS. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; This study showed, for the first time, that intranasal administration of IL-27 inhibited nasal allergic responses and symptoms even after the establishment of allergic rhinitis and suggested that IL-27 is useful as an intranasal therapeutic agent.<\/jats:p>","DOI":"10.1159\/000493398","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T22:01:25Z","timestamp":1542232885000},"page":"101-105","source":"Crossref","is-referenced-by-count":14,"title":["Intranasal Administration of IL-27 Ameliorates Nasal Allergic Responses and Symptoms"],"prefix":"10.1159","volume":"178","author":[{"given":"Motohiko","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-018-5914-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0609445"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4415"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5626"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1039-x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01839.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.12.8461"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.08.014"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.89"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1952"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-72"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1791"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/493398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/493398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:51:21Z","timestamp":1745427081000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000493398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,7]]},"published-print":{"date-parts":[[2019,2,14]]}},"URL":"https:\/\/doi.org\/10.1159\/000493398","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,14]]}}}